A2-ESO-1 TCR-Engineered T Cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for A2-ESO-1 TCR-Engineered T Cells, covering 2026-01-14 to 2026-01-14. Get the full timeline:
Most recent: Clinical Trial Update: A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer [Phase 1]